Meril's groundbreaking leap in heart valve innovation 'Myval Octapro THV' showcased at GISE 2024 and PCR London Valves

Meril Life Sciences, a leading global med-tech company specializing in cardiovascular and structural heart solutions, marked a significant milestone with the launch of its Myval Octapro Transcatheter Heart Valve (THV) at GISE 2024 (National Congress of the Italian Society of Interventional Cardiology) and PCR London Valves 2024. These esteemed scientific events provided an ideal platform for Meril to showcase its commitment to advancing structural heart care.

The Myval THV series, known for its innovative contributions to transcatheter aortic valve replacement (TAVR) procedures, continues to set new benchmarks with the Myval Octapro THV. This latest iteration introduces low frame foreshortening, enhancing operator control and enabling precise deployment for improved procedural predictability. Additionally, its comprehensive size matrix, which includes conventional, intermediate, and extra-large valve sizes, ensures optimal valve selection tailored to diverse patient anatomies.

Dr Ashok Seth of Fortis Escorts Heart Institute and D Rajneesh Kapoor of Medanta emphasized the significance of these innovations in improving patient outcomes.

At PCR London Valves 2024, Meril presented key findings from the LANDMARK trial subset analysis and comparative studies, further establishing the safety and efficacy of the Myval Transcatheter Heart Valve (THV) series. Published in EuroIntervention Journal, the findings confirmed the Myval THV’s non-inferiority to both Sapien and Evolut valve series at 30 days post-implantation, solidifying its position as a reliable solution for structural heart interventions.

Explore in-depth details about the launch of groundbreaking Myval Octapro THV at PCR London Valves 2024 by Meril. Access the complete articles here:

https://bit.ly/3Zfd8VK
https://bit.ly/3Zc2WNF